AstraZeneca’s Brilinta significantly reduced cardiovascular (CV) events and coronary death beyond one year in heart attack survivors with multi-vessel disease in a Phase III trial.
Roche said that the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death by 26% in certain people with advanced kidney cancer in a Phase III study.
Sage Therapeutics’ sleep disorder drug SAGE-217 has yielded positive results from a phase 1/2 trial in healthy adult volunteers using a 5-hour phase advance model of insomnia using polysomnography.
SillaJen has initiated a phase 1/2 clinical trial of pexastimogene devacirepvec (Pexa-Vec) in combination with checkpoint inhibitor therapy for the treatment of metastatic colon cancer.
AstraZeneca has reported top-line results from the Phase III KRONOS trial, which showed significant effect of PT010 triple combination therapy in chronic obstructive pulmonary disease (COPD).
Allergy Therapeutics has completed recruitment of patients in the PQ Birch phase III clinical trial.
BerGenBio announced that it met the first efficacy endpoint in the phase II clinical trial evaluating BGB324 (bemcentinib), a selective AXL inhibitor, in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC) who have progressed on an approved EGFR inhibitor.
Inovio Pharmaceuticals and the Parker Institute for Cancer Immunotherapy have signed a clinical collaboration agreement to assess novel combination regimens within the field of immuno-oncology.
Atara Biotherapeutics has received clearance from the US Food and Drug Administration (FDA) to initiate two phase 3 clinical studies with tabelecleucel (formerly known as ATA129) in patients with rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+PTLD).
AbbVie says that its investigational oral JAK1-selective inhibitor upadacitinib (ABT-494) has demonstrated positive results as monotherapy in phase 3 rheumatoid arthritis study, meeting all primary and key secondary endpoints.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.